Joseph D. Rager

机构：Prelude Therapeutics Incorporated (United States) · ORCID：0009-0004-6008-9630

发表论文 68 篇 · 总被引 499 次 · h-index 7

代表论文

• PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4 -Mutated Cancers (2025 · Cancer Research · 被引 20)
• Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies (2025 · Leukemia · 被引 14)
• Abstract B113: Discovery of PRT3789, a first-in-class potent and selective SMARCA2 degrader in clinical trials for the treatment of patients with SMARCA4 mutated cancers (2023 · Molecular Cancer Therapeutics · 被引 4)
• Abstract 4503: Preclinical characterization of PRT7732: A highly potent, selective, and orally bioavailable targeted protein degrader of SMARCA2 (2024 · Cancer Research · 被引 3)
• Abstract 1646: Elucidating the molecular mechanism of action of the first in human SMARCA2 selective degrader PRT3789 (2025 · Cancer Research · 被引 2)
• Abstract 1649: Discovery of first-in-class potent and selective oral degraders of KAT6A that demonstrate anti-cancer activity in pre-clinical models (2025 · Cancer Research · 被引 1)